Bone Mineral Density Response from Teriparatide in Patients with Osteoporosis

Abstract

Background

A review of data from large clinical trials reported more than 90% of subjects significantly improved their bone mineral density (BMD) at the lumbar spine (LS) with teriparatide (TPTD) (bone 39:1268–1275, 1). However, our clinical experience suggests that many patients may be non-responders, raising questions as to the true efficacy of TPTD in improving BMD in osteoporotic patients.

Questions/Purposes

The purpose of the study is to determine the rate of improvement in BMD following 18–24 months of teriparatide (TPTD) in patients with osteoporosis within an orthopedic hospital setting.

Methods

This is a retrospective chart review of patients with osteoporosis who completed 18–24 months of TPTD therapy. The primary endpoint was the change in BMD at lumbar spine (LS) and hip-femoral neck (FN) and total hip (TH) following treatment. Secondary endpoints included the effect of prior bisphosphonate therapy, age, body mass index (BMI) and family history of fracture on BMD response, and the changes in bone-specific markers during active treatment.

Results

Seventy-eight women and men with mean T-scores at the LS = −2.63 met the inclusion criteria. The overall group showed a 10.7% increase in LS-BMD after 24 months of TPTD. Eighty-three percent were considered responders defined as ≥3.0% increase in LS-BMD. Non-responders (16.7%) had mean LS-BMD change = −1.41%. No difference in baseline vitamin D, calcium, creatinine, BMI, age, gender, prior fracture history, or bisphosphonate use was observed between responders and non-responders. No consistent pattern of change in measures of bone markers was noted between responders and non-responders.

Conclusion

Eighty-three percent of patients with osteoporosis showed a >3% increase in BMD after TPTD treatment. Baseline parameters, prior bisphosphonate therapy, and the changes in bone markers showed no correlation with final BMD outcome.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Bilezikian JP, Rubin MR, Finkelstein JS. Parathyroid hormone as an anabolic therapy for women and men. J Endocrinol Invest. 2005; 28: 41-49.

    CAS  PubMed  Google Scholar 

  2. 2.

    Black DM, Bilezikian JP, Ensrud KE, et al. Rosen CJ; PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005; 353(6): 555-65.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349: 1207-1215.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Blumsohn A, Marin F, Nickelsen T, et al. González de la Vera J, Boonen S, Liu-Léage S, Barker C, Eastell R; EUROFORS Study Group. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int. 2011; 22(6): 1935-46.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Bonnick SL, Johnston CC, Kleerekoper M, et al. Importance of precision in bone density measurements. J Clin Densitom. 2001; 4: 105-10.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007; 357: 905-916.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Chen P, Miller PD, Delmas PD, et al. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21: 1785-1790.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005; 20: 962-70.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Cohen A, Stein EM, Recker RR, et al. Teriparatide for Idiopathic Osteoporosis in Premenopausal Women: A Pilot Study. J Clin Endocrinol Metab. 2013; 98: 1971-1981.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011; 26: 503-511.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002; 112: 281-9.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Dobnig H, Sipos A, Jiang Y, et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab. 2005; 90: 3970-3977.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Eastell R, Robins SP, Colwell T, et al. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int. 1993; 3: 255-260.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Gallagher JC, Rosen CJ, Chen P, et al. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone. 2006; 39: 1268-1275.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Gibbons RD, Hedeker D, DuToit S. Advances in Analysis of Longitudinal Data. Annu Rev Clin Psychol. 2010; 6: 79-107.

    Article  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Gluer CC. Monitoring skeletal changes by radiological techniques. J Bone Miner Res. 1999; 14: 1952-62.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000; 85: 3069-3076.

    CAS  PubMed  Google Scholar 

  18. 18.

    Leder BZ, Tsai JN, Neer, RM, Uihlein AV, Wallace PM, Burnett-Bowie SM. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial. Journal of Clinical Densitometry: Assessment & Management of Musculoskeletal Health 2016; 1–6.

  19. 19.

    Lenchik L, Kiebzak GM, Blunt BA. What is the role of serial bone mineral density measurements in patient management? J Clin Densitom. 2002; 5: S29-38.

    Article  PubMed  Google Scholar 

  20. 20.

    Lewiecki EM. Non-responders to osteoporosis therapy. J Clin Densitom. 2003; 6: 307-14.

    Article  PubMed  Google Scholar 

  21. 21.

    Li Z, Meredith MP, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med. 2001; 20: 3175-88.

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986; 73: 13-22.

    Article  Google Scholar 

  23. 23.

    Ma YL, Bryant HU, Zeng Q, et al. New bone formation with teriparatide [human parathyroid hormone-(1–34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology. 2003; 144: 2008-2015.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Marcus R, Wang O, Satterwhite J, et al. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res. 2003; 18: 18-23.

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Muschitz C, Kocijan R, Fahrleitner-Pammer A, et al. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density. J Bone Miner Res. 2013; 28(1): 196-205.

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Niimi R, Kono T, Nishihara A, et al. A retrospective analysis of nonresponse to daily teriparatide treatment. Osteoporos Int. 2016; 27(9): 2845-53. doi:10.1007/s00198-016-3581-z.

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18: 9-17.

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Ravaud P, Reny JL, Giraudeau B, et al. Individual smallest detectable difference in bone mineral density measurements. J Bone Miner Res. 1999; 14: 1449-56.

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Recker RR, Marin F, Ish-Shalom S, et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res. 2009; 24: 1358-1368.

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    Rubin MR, Bilezikian JP. The anabolic effects of parathyroid hormone therapy. Clin Geriatr Med. 2003; 19: 415-432.

    Article  PubMed  Google Scholar 

  31. 31.

    Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002; 17: 1-10.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Schafer AL, Sellmeyer DE, Palermo L, et al. Six months of parathyroid Hormone (1–84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. J Clin Endocrinol Metab. 2012; 97(10): 3522-9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Tsai JN, Uihlein AV, Burnett-Bowie SA, et al. Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study. J Bone Miner Res. 2015; 30(1): 39-45.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  34. 34.

    Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomized trial. Lancet. 2013; 382: 50-6.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42: 121-30.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Mr. Erik Nielsen for his assistance in collating the early patient data.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Richard Bockman MD, PhD.

Ethics declarations

Conflict of Interest

So-Young Kim, MD, Meng Zhang, PhD, and Richard Bockman, MD, PhD, have declared that they have no conflict of interest.

Human/Animal Rights

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5).

Informed Consent

Informed consent was waived from all patients for being included in the study.

Required Author Forms

Disclosure forms provided by the authors are available with the online version of this article.

Additional information

Work performed at Hospital for Special Surgery.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(PDF 1224 kb)

ESM 2

(PDF 1224 kb)

ESM 3

(PDF 1224 kb)

ESM 4

(DOCX 13 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kim, S., Zhang, M. & Bockman, R. Bone Mineral Density Response from Teriparatide in Patients with Osteoporosis. HSS Jrnl 13, 171–177 (2017). https://doi.org/10.1007/s11420-016-9537-1

Download citation

Keywords

  • bone
  • osteoporosis
  • teriparatide treatment
  • clinical outcome
  • bone markers